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Abstract
Objective To ﬁnd out if administration of melatonin
facilitates discontinuation of benzodiazepine (BD) therapy
in patients with insomnia.
Method A placebo controlled trial in nine general prac-
tices in the Netherlands. Long-term users of benzodiaze-
pines were asked by their GP to participate in a
discontinuation program in combination with melatonin or
placebo. The intervention and follow-up period lasted
one year. During this period participants received four
questionnaires about their use of sleeping medication and
several health instruments. The urine of all participants was
tested for the presence of benzodiazepines, as proof of the
discontinuation.
Main outcome measure The discontinuation of benzodi-
azepine use measured by questionnaires and urine samples
at three assessment points.
Results A total of 503 long-term users were selected by
the GPs, of whom 38 patients (16M/22F) participated.
After one year 40% had stopped their benzodiazepine use,
both in the intervention group on melatonin and in the
placebo control group. Comparing stoppers and non-stop-
pers did not reveal signiﬁcant differences in benzodiaze-
pine use, or awareness of problematic use.
Conclusion Our ﬁndings do not conclusively indicate that
melatonin is helpful for the discontinuation of the use of
benzodiazepines, but the average dose of benzodiazepines
in the group was low. Further investigation is necessary,
with special attention to the possible inﬂuence of the daily
dose on the facilitation effect of melatonin.
Keywords Discontinuation  Hypnotics  Long-term
benzodiazepine use  Melatonin  Primary care 
The Netherlands
Impact of ﬁndings on practice
• stopping long-term use of benzodiazepine hypnotics is
difﬁcult
• users of a high daily dose might be more responsive to
the effect of melatonin on the discontinuation of
benzodiazepines
• investigators should take into account the difﬁculty of
recruiting patients for studies on discontinuing the use
of benzodiazepines
Introduction
The point prevalence of the use of sleeping medication,
often benzodiazepines (BD), in countries such as the
Netherlands is approximately 6% [1], with over one-third
being long-term users. This does not meet the standard of
the Dutch Society of General Practitioners, which advises
that hypnotics should not be prescribed longer than for a
period of 10 days [2]. After a minimal intervention strategy
such as sending an educational letter, one in every four
users stops [3–5]. As an aid to discontinuation, several
treatments have been used, e.g., certain drugs [6] and
cognitive therapy [7], without added value.
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endogenous biological clock, located in the suprachias-
matic nuclei of the hypothalamus and inﬂuenced by light
and darkness to the body [8]. Suprachiasmatic projections
regulate the pineal gland and its production of melatonin.
The primary physiological function of melatonin is to
convey information about the daily cycle of light and
darkness to the body’s physiology. Melatonin production
changes with age and is lower in the elderly. Its secretion is
high during the night and has an effect on falling asleep.
There is evidence that low doses of melatonin improve
initial sleep quality in selected elderly insomniacs [9].
Some BDs have shown to have a negative effect on
melatonin production in the pineal gland [8].
Garﬁnkel et al. [10] investigated stopping the chronic
use of BD sleeping medication with the help of melatonin
(5 mg). In their randomized discontinuation trial melatonin
appeared efﬁcacious: 14 of 18 (78%) patients on melatonin
stopped their BD compared to 4 out of 16 (25%) in a
placebo control group.
A study in elderly patients of Cardinali et al. [11] does
not support efﬁcacy of melatonin to reduce the use of
benzodiazepines in low doses. Forty-ﬁve patients were
randomized to receive either melatonin (3 mg) or placebo
for six weeks. In two steps BD was tapered off and stopped
after four weeks. Several sleep parameters were assessed
and found not to be different for both groups.
The administration of melatonin as a sleeping medica-
tion is a contradictory tool to help people discontinue use
of BDs.
Aim of the study. The main research question in our trial
was whether melatonin is helpful in discontinuing the use
of BD sleeping medication, looking at the stopping rate.
Secondary objectives are ﬁnding the possible inﬂuence of
other variables on stopping, such as age, gender, period of
BD use, and dependence on BD. Besides, we investigated a
putative shift of addiction, e.g., to alcohol or smoking.
Method
Our study was designed as a randomized placebo-con-
trolled discontinuation trial. We gathered data in nine
general practices (2001–2004). The patients, their GPs and
the principal investigator were blinded for the study med-
ication. All practices were located in Maastricht, in the
south of the Netherlands.
Included are adult patients who used BD as a sleeping
medication for more than three months (deﬁned as long-
term use) with a minimum use of three days per week.
Patients were selected via their GPs, in six practices
through the desk prescriptions, in two on the basis of a
pharmacy print out, and in one through the problem list in
the medical ﬁle on the ICPC-code P17 (drug addiction)
[12]. Exclusion criteria were the use of more than one BD
at the same time, use of another type of sleep medication,
use of stimulants and, according to their GP, alcohol
misuse, serious mental/somatic disease or unﬁt to
participate.
All patients who were selected received an invitation
letter from their GP that also informed them of the disad-
vantages of long-term use of BD. A short questionnaire
was added to check the inclusion criteria. All respondents
meeting the inclusion criteria received by mail a ques-
tionnaire (T0): about the use of sleeping medication, sleep
complaints (SWEL) [13], sleep quality [14], general health
experience (RAND-36) [15], BD dependence (Bendep-
SRQ) [16] and habit formation (amount of alcoholic con-
sumptions and/or cigarettes/cigars per day). The sleep
wake experience list (SWEL) is a validated instrument to
study chronic sleep complaints (insomnia, hypersomnia or
the combination of those two). The benzodiazepine
dependence self-report questionnaire (Bendep-SRQ) is a
validated instrument to measure BD dependency, scoring
in subscales the degree of awareness of problematic BD
use, degree of preoccupation with respect to the availability
of BDs, degree of lack of compliance with the therapeutic
BD regimen, and the degree of unambiguity of experienced
BD withdrawal (Bendep-SRQ, scale 4)
At the end of the questionnaire, we asked speciﬁcally
whether the patient was willing to discontinue use of BDs.
Participants had to send back an informed consent form.
All participants were checked for liver and kidney function
and their urine was tested for BD with a ﬂuorescence
polarization immunoassay (FPIA) [17].
After returning the informed consent, patients were in-
cluded for random allocation.
The use of sleeping medication at the start of the study
was compared with the deﬁned daily dose (DDD) of the
patient’s hypnotic. It was expressed as a quotient of pre-
scribed daily dose (PDD) relative to the deﬁned daily dose,
i.e., PDD/DDD. The PDD was based on the completed
questionnaire (T0). We created three categories using this
quotient: low (quotient £ 0.5), average (0.5 < quo-
tient < 1.0) and high use (quotient ‡ 1.0).
All participants received a stopping scheme of their BD
via their own pharmacy. Their BD was converted to an
equivalent dose of diazepam [18] that was stabilized for
two weeks and then further converted every two weeks to
75%, 50%, 25%, 12.5% and 0% of the original dose. We
added 5 mg melatonin or placebo which had to be taken
4 h before patients went to bed. After stopping BD we
continued the use of melatonin or placebo for six more
weeks. Furthermore a questionnaire was sent at 18 weeks
(T1), 26 weeks (T2) and 52 weeks (T3) after the beginning
of the discontinuation. All questionnaires contained the
642 Pharm World Sci (2007) 29:641–646
123same set of instruments. Also urine samples for BD
determination were required at T1 and T3.
Results
The GPs selected 503 patients for our trial, 138 males and
365 females. Of these, 80% responded to our invitation
letter (Fig. 1). Six patients reported to have stopped their
use of sleeping medication already. Sixteen patients used
two or more BDs, and were excluded from the study. Of all
responders, 124 appeared to be willing to participate.
Receiving the ﬁrst questionnaire of these 124 patients,
22 did not respond, 56 decided not to participate and eight
patients did not meet the inclusion criteria (six of whom
had already stopped the BD use). At the end, only 38
participants (16 males and 22 females) were indicated to
take part in the study. They were randomly allocated to
melatonin or placebo.
The participants compared to the non-participants were
more often males (40% vs. 25%), and had a lower age
(<50 years, 16% vs. 5%) and less elderly (>80 years, 5%
vs. 18%). Of the total group, 76% were 60 years or older.
The characteristics of all participants are listed in
Table 1. No differences were found between the melatonin
and the placebo group. The sleep quality was rated bad in
58% of the cases. According to the SWEL 10 of the 38
participants reported that they did not have any sleeping
complaints (any more) Of the other 28, 18 complained of
insomnia, three of hypersomnia, and seven of a combina-
tion of both. Most participants (76%) used a low dose of
BD (PDD/DDD < 1.0). According to the score on the
Bendep-SRQ list, 61% of the participants were aware that
they had problematic BD use.
Twenty-two participants had tried to stop BD use in the
past, and 12 of them experienced a high level of with-
drawal symptoms.
In total 21 patients discontinued the use of BD after the
taper off: 12 in the melatonin group and nine in the placebo
group (Table 2). After one year 15 patients remained
(40%) without BD sleeping medication (eight out of 20 in
the melatonin group and seven out of 18 in the placebo
group). This difference was not signiﬁcant.
The urine analysis showed that two patients in the pla-
cebo group, who had reported that they had stopped using
BD, were still positive. They had received new prescrip-
tions of BD at one and three months after T3, although at a
lower dose.
At the end of the trial three persons used melatonin, two
in the melatonin group and one in the placebo group. Of the
Abbrevations used: 
nr1:   did not respond to initial invitation letter 
nr2:   did not respond to second invitation after initially agreeing to participate  
np1:   did not want to participate  
np2:   did not want to stop BD use after an initial positive response (informed consent)  
nmi1 and nmi2: did not comply with inclusion criteria: did not use BD as sleeping medication; used BD less 
than three times per week; used more than one BD at the same time; used other sleeping 
medication; has stopped using BD in the meantime; or has gone to another practice 
placebo
group
n=18
nr2 22 
np2 56 
nmi2 8 
participants 
n=38
nr1 95 
np1 113 
nmi1 171 
potential
participants 
N=124
selected by GPs 
N=503
melatonin
group
n=20
randomization
Fig. 1 Selection of patients and
response/non-response;
participants
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123Table 1 Characteristics of the 38 participants, and for melatonin and placebo separately
Melatonin group n =2 0
numbers (%)
Placebo group n =1 8
numbers (%)
Total participants n =3 8
numbers (%)
Gender Male 6 (30) 10 (56) 16 (42)
Female 14 (70) 8 (44) 22 (58)
Age in years <50 3 (15) 3 (17) 6 (16)
50–59 3 (15) 3 (17) 6 (16)
60–69 6 (30) 7 (39) 13 (34)
70–79 7 (35) 4 (22) 11 (29)
‡80 1 (5) 1 (5) 2 (5)
Health insurance National health insurance 16 (80) 18 (100) 34 (90)
Private insurance 4 (20) – 4 (10)
Sleep quality Good 7 (35) 5 (28) 12 (32)
Bad 11 (55) 11 (61) 22 (58)
2 missing 2 missing 4 missing
Period of use of BD <1 year – – –
1–5 years 7 (35) 7 (39) 14 (37)
6–9 years 4 (20) 4 (22) 8 (21)
‡10 years 9 (45) 6 (34) 15 (39)
1 missing 1 missing
Daily use of BD (PDD/DDD) £ 0.5 (low) 11 (55) 14 (78) 25 (66)
0.5–1.0 (moderate) 4 (20) – 4 (10)
‡1.0 (high) 5 (25) 4 (22) 9 (24)
Smoking Yes 9 (45) 7 (39) 16 (42)
No 10 (50) 11 (61) 21 (55)
1 missing 1 missing
Alcohol use Yes 15 (75) 15 (83) 30 (79)
No 5 (25) 3 (17) 8 (21)
Body mass index (BMI) Normal 8 (40) 10 (56) 18 (47)
BMI > 25 12 (60) 8 (44) 20 (53)
Problematic BD use (subscale of
Bendep-SRQ)
Low 6 (30) 2 (11) 8 (21)
Average 3 (15) 2 (11) 5 (13)
High 11 (55) 13 (72) 23 (61)
1 missing 1 missing
None of the differences were statically signiﬁcant at the 5% level (v
2-test)
Table 2 Follow up after one year. Use of BD sleeping medication after the taper off and during follow up. Separate data for the melatonin and
placebo group
Stopped on T1 Did not resume on T2 Deﬁnitely stopped on T3 Melatonin
*** on T3
Melatonin group (n = 20) 12 10 8* 2
Placebo group (n = 18) 9 7 7* (1**) 1
Total 21 17 15 3
T1 = at the time of stopping the use of melatonin or placebo (six weeks after the taper off of BD)
T2 = after six months
T3 = after one year
* One person in the placebo group and one in the melatonin group stopped participation in the trial after the taper off. According to their GPs,
they no longer used any BD at T3
** One person had resumed using BD at T2, but stopped again at T3. He is not counted as a deﬁnite stopper
*** Three persons received melatonin from their GP after discontinuing the use of melatonin in the trial
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123patients who had stopped, four had switched to a herb
product (valerian, Valdispert
 ) or homeopathic product
(Nervogin
 , passiﬂora).
The patients who had totally discontinued BD use were
compared with the non-stoppers in terms of gender, age,
weight, period of use, PDD, sleeping quality, general
health experience and awareness of problematic use. We
found small differences, which were not statistically sig-
niﬁcant at the a = 0.05 level (Table 3). Of the patients who
had already used BD for ﬁve years or more, 35% stopped
compared to 43% of the patients with a shorter period of
use. For high daily use (PDD/DDD ‡ 1), this was 33%
compared to 41% for daily use <1. Of the patients who
were aware of their problematic use, 54% stopped com-
pared to 29% among the others.
Four of the 19 patients who had stopped at T1 reported a
high level of withdrawal symptoms during the taper off.
We have no data for two people because they did not
complete the questionnaire.
To measure the effects of discontinuation we compared
the scores of T0 (initial measurement) with those at T3
(ﬁnal measurement). In terms of health experience, there
were no differences between the stoppers and non stoppers
according to the scores on nine scales of the RAND
questionnaire, sleeping quality, alcohol consumption, or
smoking.
Discussion
In our trial, we could not conﬁrm the positive outcome of
Garﬁnkel et al. [10]. Our ﬁndings are in agreement with
those of Cardinali et al. [11].
The success rate of our study was 40%, higher than of
that of spontaneous stopping (10–15%) [19, 20] and stop-
ping after an informative letter or minimal intervention
strategy (25%) [3–5]. This may be caused by the use of our
taper-off program, the selection by some GPs and the
selective response, including the awareness of problematic
use (in two-thirds of the participants). In general, readiness
to stop using BD sleeping medication was low. In our trial
we fell well short of the discontinuation rate in the mela-
tonin group of the trial of Garﬁnkel et al. (14 out of 18).
After a minimum intervention, it appears that of the
stoppers after two years only half remain without this
medication [21]. In our trial, 55% of the participants had
stopped shortly after the taper off. However, after a year
this dropped to 40%. We omitted any supportive measures
during follow up as much as possible in order to measure
the pure effect of melatonin.
The gender difference in our selected population
(n = 503) is comparable to ﬁgures in the literature [1]. BD
use among Garﬁnkel et al.’s patients was higher than ours
(only nine of our patients had PPD/DDD ‡ 1.0). It has been
shown that patients on a rather low dose of BD discontinue
their use more easily and resume their BD use less rapidly
[21]. For patients with a high daily use melatonin may still
be valuable. If there will be future discontinuation trials
there is reason to especially include patients who use a high
dose of BD.
In our trial, in contrast to that of Garﬁnkel et al., at the
end only 9% still used melatonin. Four participants chan-
ged their use to a homeopathic or phytotherapeutic medi-
cation, which indicates a basic need to use something for
their sleeping problem.
Half of the patients who tried to stop by themselves
before participating in our study, without taper off, suffered
from withdrawal symptoms. In our trial this was 25%,
showing the advantage of gradual tapering. We did not ﬁnd
a shift of addiction behavior, sleep quality or general health
among stoppers of BD.
Conclusions
Our trial does not provide conclusive evidence that mela-
tonin is helpful for BD discontinuation.
The overall question about the effectiveness of inter-
vention remains. Another trial, in contrast to the ﬁrst trial,
shows a negative result. One should consider that the
results of all three trials are inﬂuenced by a possible
Table 3 Putative indicators of discontinuation of benzodiazepines
(numbers and percentages)
Deﬁnite
stoppers
Non-
stoppers
Total
Male 6 (38%) 10 (62%) 16
Female 9 (41%) 13 (59%) 22
Age <65 6 (33%) 12 (67%) 18
Age 65+ 9 (45%) 11 (55%) 20
Body mass index <25 6 (33%) 12 (67%) 18
Body mass index ‡25 9 (45%) 11 (55%) 20
Period of use <5 year 6 (43%) 8 (57%) 14
Period of use ‡5 year 8 (35%) 15 (65%) 23 (1 missing)
PDD/DDD < 1.0 12 (41%) 17 (59%) 29
PDD/DDD ‡ 1.0 3 (33%) 6 (67%) 9
Awareness of problematic
use, low
7 (29%) 17 (71%) 24
Awareness of problematic
use, high
7 (54%) 6 (46%) 13 (1 missing)
General health, low 6 (40%) 9 (60%) 15
General health, high 9 (41%) 13 (59%) 22 (1 missing)
Sleeping quality, bad 8 (36%) 14 (64%) 22
Sleeping quality, good 6 (50%) 6 (50%) 12 (4 missing)
None of the differences were statistically signiﬁcant at the 5% level
(v
2 test)
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123selection bias or lack of power, due to the low number of
participants.
Further investigation is necessary, with special attention
to the effect of the daily dose on stopping the use of BD.
Finally one should take into account the difﬁculty of
recruiting BD users for stop studies.
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